Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 3:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 545 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: HIV in Adults Clear all
Completed Phase 2 Interventional Results available

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

NCT01641809
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GSK1265744 10 mg, GSK1265744 30 mg, GSK1265744 60 mg, Efavirenz 600 mg, Rilpivirine 25 mg, Placebo, Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Oct 10, 2026, 3:47 PM EDT
Completed Phase 1 Interventional

Study of How Indinavir (an Anti-HIV Drug) and Rifabutin (a Drug Used to Treat MAC, an HIV-Associated Disease) Interact in HIV-Positive and HIV-Negative Adults

NCT00000877
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Rifabutin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
8
States / cities
Los Angeles, California • Denver, Colorado • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 10, 2026, 3:47 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Safety and Immunogenicity of a Higher Dose of the Study Vaccine, VIR-1388, in HCMV-seropositive Adult Participants Without HIV

NCT07801456
View directory record Official record
Conditions
Cytomegalovirus (CMV), HIV (Human Immunodeficiency Virus)
Interventions
VIR-1388, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Birmingham, Alabama • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 10, 2026, 3:47 PM EDT
Completed No phase listed Observational

Long-Term Data Collection From Participants in Adult AIDS Clinical Trials

NCT00001137
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
13 Years and older
Enrollment
5,982 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
75
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2013 · Synced Oct 10, 2026, 3:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Drug Interaction Study With Efavirenz

NCT01098526
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions
GSK1349572, Efavirenz
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 10, 2026, 3:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

NCT00252148
View directory record Official record
Conditions
HIV Infection
Interventions
ADMVA
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 40 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
2
States / cities
New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 10, 2026, 3:47 PM EDT
Completed No phase listed Observational

Treatment De-Intensification and Residual HIV-1 in Youth

NCT00867854
View directory record Official record
Conditions
HIV-1, HIV Infections
Interventions
Blood draw
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 24 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 10, 2026, 3:47 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants

NCT05217641
View directory record Official record
Conditions
HIV Infections
Interventions
BG505 MD39.3 mRNA, BG505 MD39.3 gp151 mRNA, BG505 MD39.3 gp151 CD4KO mRNA
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 10, 2026, 3:47 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers

NCT02634073
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Lamivudine, Sorbitol
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 10, 2026, 3:47 PM EDT
Completed Phase 4 Interventional

Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1

NCT03502005
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
bictegravir/emtricitabine/tenofovir alafenamide
Drug
Lead sponsor
Midland Research Group, Inc.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Oakland Park, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 10, 2026, 3:47 PM EDT
Completed Phase 2 Interventional Results available

Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients

NCT00752856
View directory record Official record
Conditions
HIV Infections
Interventions
Kaletra + Isentress, Atripla
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
6
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 10, 2026, 3:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Acceptance and Commitment Therapy for Aging People Living With HIV in Chronic Pain

NCT03699020
View directory record Official record
Conditions
HIV/AIDS, Chronic Pain
Interventions
Acceptance and Commitment Therapy (ACT), Chronic Pain Education
Behavioral · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 10, 2026, 3:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants

NCT04212091
View directory record Official record
Conditions
HIV Infections
Interventions
PGT121.414.LS, VRC07-523LS
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Decatur, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 10, 2026, 3:47 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants

NCT05418868
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir 200 mg/mL, Cabotegravir >=400 mg/mL, Cabotegravir Formulation I, CAB Formulation J, rHuPH20, RPV
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
3
States / cities
Orlando, Florida • Las Vegas, Nevada • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 10, 2026, 3:47 PM EDT
Not yet recruiting Not applicable Interventional

Auricular Point Acupressure for Pain

NCT07852611
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus), Pain
Interventions
Auricular Point Acupressure, Sham Auricular Point Acupressure
Other
Lead sponsor
Dan Song
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Corpus Christi, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 10, 2026, 3:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of High Fat Meal on Cabotegravir

NCT02799264
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Cabotegravir 30 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 10, 2026, 3:47 PM EDT
Terminated Phase 4 Interventional

Treatment of Anemia and Neutropenia in HIV/HCV Coinfected Patients Treated With Pegylated Interferon and Ribavirin

NCT00194857
View directory record Official record
Conditions
Anemia, Neutropenia, Hepatitis C Virus, HIV Infections
Interventions
erythropoietin, GCSF
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 10, 2026, 3:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected Adults

NCT02960581
View directory record Official record
Conditions
HIV Infection
Interventions
PGT121 3mg/kg IV, PGT121 10mg/kg IV, PGT121 30mg/kg IV, PGT121 3mg/kg SC, Placebo (0.9% Sodium Chloride Injection USP (Saline))
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 10, 2026, 3:47 PM EDT
Completed Not applicable Interventional

Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults

NCT00051831
View directory record Official record
Conditions
HIV Infections
Interventions
Emtricitabine, Enfuvirtide, Ritonavir, Saquinavir, Tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 10, 2026, 3:47 PM EDT
Completed Phase 3 Interventional Results available

Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir

NCT01568892
View directory record Official record
Conditions
HIV Infections
Interventions
Dolutegravir 50 mg twice daily, Dolutegravir placebo twice daily
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
25
States / cities
Little Rock, Arkansas • Bakersfield, California • Beverly Hills, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 10, 2026, 3:47 PM EDT
Completed Phase 2 Interventional

A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome

NCT00002127
View directory record Official record
Conditions
HIV Infections, HIV Wasting Syndrome
Interventions
Thalidomide
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Greenbrae, California • Redwood City, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 10, 2026, 3:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP300 and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers

NCT00001072
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC-HIV MN120TMGNP (vCP300), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1999
U.S. locations
6
States / cities
Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 10, 2026, 3:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Transitioning HIV+ Adolescents to Adult Care: Exploring Adolescent and Adult Medicine Clinics Role in the Process

NCT02785302
View directory record Official record
Conditions
HIV
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 24 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
14
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 10, 2026, 3:47 PM EDT
Completed Not applicable Interventional Results available

High-Intensity Exercise to Attenuate Limitations and Train Habits in Older Adults With HIV

NCT04550676
View directory record Official record
Conditions
Hiv, Fatigue, Mobility Limitation
Interventions
HIIT (intervention), CME (active control), Coaching, Control text message
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 10, 2026, 3:47 PM EDT